PFE's non-COVID drugs and contributions from new and newly acquired products are likely to have driven top-line growth in the ...

Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by ...

Bernstein analyst Courtney Breen maintained a Hold rating on Pfizer (PFE – Research Report) yesterday and set a price target of $32.00. The ...

Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from ...

Pfizer Inc. (NYSE:PFE), one of the world's largest pharmaceutical companies with a market capitalization of $151.25 billion, finds itself at a critical juncture as it navigates the post-pandemic ...

The former President of Pfizer Global Manufacturing gifted $50 million to his former school, Northfield Mount Hermon.

Pfizer (NYSE:PFE – Get Free Report) had its price objective decreased by equities research analysts at Citigroup from $30.00 ...

Financial analysis of Pfizer Inc. stock ahead of its earnings release. PFE faces significant headwinds from patent expiries, click for my updated look at the stock.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Pfizer Inc. (NYSE:PFE – Get Free Report)’s share price traded down 0.6% during trading on Tuesday after Citigroup lowered their price target on the stock from $30.00 to $29.00. Citigroup currently has ...

Analyst Tim Anderson from Bank of America Securities reiterated a Hold rating on Pfizer (PFE – Research Report) and keeping the price target at ...

Pfizer said it will 'support capacity-building initiatives, such as training healthcare professionals and advancing clinical ...